GEPL’s pick of the week is Indoco Remedies Ltd recommended at the price of Rs 505 and a target of Rs 750 over the next 12 months. Indoco is one of the fastest growing pharma companies manufacturing finished dosage forms and API aptly placed to tap the huge opportunity visible in the generic space. It is strongly placed in the domestic space that contributes around 70% of the revenues. The Company is undertaking expansions across its different business segments which should further help it cater to increasing demand. The company has entered into dossier and licensing deals with Watson and Aspen Pharmacare with a gradual ramp up in the deal size placing the company in a better position to cater to a wider range of markets. These would be the key growth drivers for the company once the approvals and regulatory issues are in place. Thus, with the organic growth being intact and increasing business through alliances with MNC’s we stand positive on the company and recommend a BUY on the stock.
Published by geplcapital
Offering a range of financial services across investment spectrum, GEPL is a boutique financial services and investment advisory firm. It covers products such as equities, mutual funds, bonds, currencies, derivatives, commodities, wealth management, insurance, real estate, loan against securities and Demat services. GEPL provides single point access to all platforms through its mobile app & web platform, sound fundamental and technical reports, anytime / anywhere trade access & easy support over phone. Established in 1997, GEPL is headquartered in Mumbai, spread across 9 states and services through 150 access points including 25 own branches. With clientele ranging from individual investors to enterprises to institutions, GEPL intuitively understands different financial requirements and offers customized investment solutions. GEPL is firmly rooted by its 3 Mantras: Servicing, Integrity and Teamwork - all of which work to the benefit of clients. Apart from these 3 pillars, GEPL has combined it’s traditional advisory with modern technology and cutting edge research to meet and surpass it’s clients expectation. View all posts by geplcapital